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Abstract
Background: Studies from iodine-sufficient areas have shown that a high proportion of patients taking medication
for thyroid diseases have thyroid stimulating hormone (TSH) levels outside the reference range. Next to patient
compliance, inadequate dosing adjustment resulting in under- and over-treatment of thyroid disease is a major
cause of poor therapy outcomes. Using thyroid function tests, we aim to measure the proportions of subjects, who
are under- or over-treated with thyroid medication in a previously iodine-deficient area.
Findings: Data from 266 subjects participating in the population-based Study of Health in Pomerania (SHIP) were
analysed. All subjects were taking thyroid medication. Serum TSH levels were measured using
immunochemiluminescent procedures. TSH levels of < 0.27 or > 2.15 mIU/L in subjects younger than 50 years and
< 0.19 or > 2.09 mIU/L in subjects 50 years and older, were defined as decreased or elevated, according to the
established reference range for the specific study area. Our analysis revealed that 56 of 190 (29.5%) subjects treated
with thyroxine had TSH levels outside the reference range (10.0% elevated, 19.5% decreased). Of the 31 subjects
taking antithyroid drugs, 12 (38.7%) had TSH levels outside the reference range (9.7% elevated, 29.0% decreased).
These proportions were lower in the 45 subjects receiving iodine supplementation (2.2% elevated, 8.9% decreased).
Among the 3,974 SHIP participants not taking thyroid medication, TSH levels outside the reference range (2.8%
elevated, 5.9% decreased) were less frequent.
Conclusion: In concordance with previous studies in iodine-sufficient areas, our results indicate that a considerable
number of patients taking thyroid medication are either under- or over-treated. Improved monitoring of these
patients’ TSH levels, compared to the local reference range, is recommended.
Background
Hypothyroidism and hyperthyroidism are common dis-
eases, which are treated with hormone replacement or
antithyroid drugs, respectively. Applied therapies are tar-
geted at adjusting the serum thyroid stimulating hor-
mone (TSH) concentration to values within the
r e f e r e n c er a n g e .H o w e v e r ,s t u d i e sf r o mt h eU . S .[ 1 , 2 ]
and the U.K. [3,4] investigating therapy outcome have
found that a considerable proportion of patients taking
medication for thyroid diseases have TSH levels outside
the reference range. In the U.S. National Health and
Nutrition Examination Study (NHANES), about one-
third of the 820 participants who reported having thyr-
oid disease or taking thyroid medication, had TSH levels
outside the reference range [2]. In the Colorado Thyroid
D i s e a s eP r e v a l e n c eS t u d y , 40% of the 1,525 subjects
undergoing thyroid hormone replacement or antithyroid
drug therapy had either elevated or decreased TSH
levels [1]. Next to patient compliance, inadequate dosing
adjustment resulting in under- and over-treatment of
thyroid diseases is a major cause of poor therapy
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practices in the U.K. [3,4], more than 20% of patients
taking thyroxine had suppressed TSH levels. The
authors concluded that taking medication for hypothyr-
oidism is, therefore, associated with an elevated risk for
hyperthyroidism [3,4].
Previously, Germany was an iodine-deficient region
[5]. While salt iodinization was introduced in the U.S. in
1924 [6], Germany’s first prophylactic measures were
not introduced until the 1980s [5]. These measures were
mandatory in the former eastern part and voluntary in
the former western part of the country. After reunifica-
tion in 1989, the principle of voluntary iodine prophy-
laxis was adopted throughout the entire country. At the
beginning of the 1990s, Germany’si o d i n es u p p l yw a s
still inadequate, causing a high prevalence of diseases
related to iodine deficiency [5]. Since the use of iodised
salt became more widespread in 1994, iodine intake has
improved markedly and in 1996, Germany’si o d i n es u p -
ply was almost adequate [5]. Today, with the exception
pregnant women and other subgroups with higher
demand [7], an adequate iodine intake is assured in the
German population.
Among the 4,310 participants of the Study of Health
in Pomerania (SHIP), 35.9% were diagnosed with goitre,
and 20.2% with thyroid nodules [8]. The prevalence of
hypo- and hyperthyroidism among subjects without
known thyroid disease was 1.2%, and 2.2%, respectively.
The high prevalence of thyroid disorders can be
explained by the insufficient iodine supply in previous
decades [8]. Under- or over-treatment due to inadequate
thyroid therapy monitoring may result in a disturbance
of the thyroid hormone profile. Therefore, we aim to
examine thyroid function in subjects taking thyroid
medication in West Pomerania, a previously iodine-
deficient area of Europe.
Methods
Study Population
SHIP is a population-based study, conducted in West
Pomerania, in northeast Germany. At the time of sam-
pling (1996), the entire population living in the area was
158,864 adults between 20-79 years. Using a two-stage
cluster sampling method, adopted from the WHO
MONICA Project Augsburg, Germany, a sample of
7,008 men and women was selected, of which 4,310
individuals participated (68.8% of eligible subjects) [9].
All participants gave written informed consent. Data
collection started in October 1997 and was finished in
May 2001. The study conformed to the principles of the
Declaration of Helsinki, as reflected by an ap r i o r i
approval of the Ethics Committee of the Board of Physi-
cians Mecklenburg-Pomerania at the University of
Greifswald.
Information on medical history, behavioural and
socio-demographic characteristics was obtained using a
computer-aided personal interview. Of 4,310 SHIP parti-
cipants, 285 reported thyroid medication use according
to the anatomical therapeutic chemical (ATC) code for
thyroid therapy (H03). None of these 285 participants
were affected by thyroid cancer, central hypothyroidism,
or pituitary disease. Eight subjects reported a history of
radio-iodine therapy, 86 reported a history of thyroid
surgery, and two reported a history of both. Among the
subjects for whom the year of surgery is known
(n = 83), almost all (96.4%) underwent thyroid surgery
more than one year prior to the SHIP examination.
Further details on the start date, duration, and medical
indication for thyroid therapy were not collected.
We excluded nine subjects from the analysis. Two
subjects could not be assigned to any thyroid medica-
tion category (thyroxine, antithyroid drugs or iodine
supplementation), and seven were excluded for using
combinations of these medications. Another ten of the
remaining 276 subjects were excluded because their
TSH level had not been measured. This resulted in a
study population of 266 subjects taking thyroid medica-
tion with TSH measurements. Among those, 219 were
females between the ages of 22 and 80 years (mean 55.1
years), and 47 were males between the ages of 28 and
81 years (mean 60.0 years). For the purpose of compari-
son, we contrasted their results with those of the partici-
pants not taking thyroid medication, including subjects
with unknown thyroid disease. Among those partici-
pants, TSH levels were available for 3,974 of 4,025 sub-
jects. That population included 1,932 females between
the ages of 20 and 81 years (mean 47.9 years) and 2,042
males between the ages 20 and 80 years (mean 50.6
years).
Laboratory methods
Between 7:00 a.m. and 4:00 p.m., non-fasting blood sam-
ples were drawn from the cubital vein of subjects in the
supine position. Thyroid function was evaluated by mea-
surement of serum TSH, free triiodothyronine (FT3),
free thyroxine (FT4), and auto-antibodies to thyroperoxi-
dase (TPOAb). We focused on the TSH level in our
analysis, as it provides adequate information for screen-
ing and monitoring of thyroxine replacement or sup-
pression therapy [10].
Serum TSH levels were measured using an immuno-
chemiluminescent assay (Byk Sangtec Diagnostica
GmbH, Frankfurt, Germany). The assay was performed
according to the manufacturer’s recommendations on a
LIA-mat analyzer. The functional sensitivity of the assay
is specified as 0.02 mIU/L. The reference range provided
by the manufacturer was 0.3-3.0 mIU/L, and the refer-
ence range specifically established for the SHIP
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than 50 years and 0.19-2.09 mIU/L in subjects 50 years
and older [11]. The SHIP-specific reference interval
represents the central 95% range between the 2.5
th and
97.5
th percentile from 1,488 subjects without known
thyroid disease and without a diagnosed thyroid disorder
as assessed by the SHIP examination [11]. Values out-
side the reference intervals were considered decreased
or elevated. A TSH level less than 0.1 mIU/L was con-
sidered suppressed.
Statistical Methods
Due to the skewed distribution of the TSH values, we
routinely report median values. Median, 25
th,7 5
th per-
centiles and the range of TSH levels are presented by
sex and thyroid medication type. Additionally, the pro-
portion of subjects with TSH levels outside the refer-
ence interval is expressed as percent values. All
statistical analyses were performed with SAS 9.1 (SAS
Institute Inc., Cary, NC, USA).
Results
The majority (71%) of the 266 SHIP participants taking
thyroid medication were treated with thyroxine (Table
1). Another 12% of subjects took antithyroid drugs, and
17% received iodine supplementation (Table 1 and Fig-
ure 1). Participants were not asked for their daily dosage
of their thyroid medication, but they were asked for the
name of the preparation. Thyroxine preparations taken
by SHIP participants contained 25-200 μg levothyroxine
(23.2% in combination with iodine, 8.9% in combination
with liothyronine), antithyroid drugs contained 5-20 mg
thiamazol and iodine preparations contained 100-200 μg
iodine.
In subjects taking thyroid medication, TSH levels ran-
g e df r o m0 . 0 2t o1 1 . 3 0m I U / L .T S Hl e v e l sw e r ew i t h i n
the SHIP reference range in 70.5% of the subjects taking
thyroxine, in 61.3% of those taking antithyroid drugs
and in 88.9% of patients receiving iodine supplementa-
tion (Figure 1). TSH levels were elevated in 10.0% of
subjects taking thyroxine, in 9.7% of those taking antith-
yroid drugs and in 2.2% of patients receiving iodine sup-
plementation. Decreased TSH values were observed in
19.5% of subjects taking thyroxine, in 29.0% of those
taking antithyroid drugs and in 8.9% of subjects receiv-
ing iodine supplementation. Suppressed TSH levels were
found in 34 individuals of whom 71% were treated with
thyroxine, followed by 26% taking antithyroid drugs, and
3% with iodine supplementation (data not shown).
When the manufacturer’s reference range was used
instead of the SHIP-specific reference range, normal
TSH levels were less frequent and decreased TSH levels
were more frequent (Figure 2). This was observed for all
classes of thyroid medication, while higher proportions
of elevated TSH were only observed in patients using
thyroxine or iodine supplementation. In subjects taking
antithyroid drugs, the proportion of patients with ele-
vated TSH levels was the same regardless of whether
the SHIP-specific or the manufacturer’s reference range
was used.
In total, 27.4% of SHIP participants taking thyroid
medication had TSH values outside the local reference
range (8.6% elevated, 18.8% decreased). Using the manu-
facturer’s reference range, 32.7% of the subjects had an
elevated (3.8%) or a decreased (28.9%) TSH level.
Among the SHIP participants not taking thyroid medi-
cation, the proportion of subjects with TSH levels out-
side the reference range was substantially lower (8.7%
SHIP-specific, 12.2% manufacturer’s).
Discussion
As seen in previous studies [1,2,12], our results indicate
that a considerable proportion of subjects taking thyroid
medication are either under- or overtreated. About
27.4% of the SHIP participants taking thyroid medica-
tion had TSH levels outside the local reference range.
Among the participants on thyroxine, nearly one-fifth
(19.5%) were over-treated, as indicated by decreased
TSH levels. Another 10.0% had elevated TSH values. In
t h i sg r o u pi tw a sn o tp o s s i b l e to differentiate between
poor compliance and under-treatment. In subjects tak-
ing antithyroid drugs, TSH levels can remain suppressed
for weeks or months after the initiation of therapy [13].
Therefore, it would have been preferable to include the
duration of treatment in the analysis. However, this
information was not gathered, and such an analysis was
not possible.
Table 1 TSH distribution in the study population
separated by type of thyroid medication
Type of thyroid medication TSH [mIU/L]
Min 25% Median 75% Max
Thyroxine
Male (n = 36) 0.02 0.31 0.60 1.47 2.99
Female (n = 154) 0.02 0.25 0.47 1.10 11.30
Antithyroid drugs
Male (n = 4) 0.02 0.07 0.54 5.34 2.99
Female (n = 27) 0.02 0.13 0.56 1.21 11.30
Iodine supplementation
Male (n = 7) 0.27 0.35 0.65 0.99 1.76
Female (n = 38) 0.04 0.35 0.53 0.80 2.11
None
Male (n = 2042) 0.02 0.43 0.65 0.94 54.00
Female (n = 1932) 0.02 0.46 0.69 1.01 86.00
TSH, serum thyroid stimulating hormone; Min, minimum; Max, maximum
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terns and prevalence of thyroid disorders [14]. In pre-
viously iodine-deficient regions, such as Germany,
hyperthyroidism caused by goitre and thyroid nodules is
common [8,15]. In regions with high or previously high
iodine intake, such as the U.S. [16] or Iceland [14], a
lower prevalence of hyperthyroidism and a higher preva-
lence of hypothyroidism have been reported [2,14].
Differences in iodine intake and thyroid disorders
are reflected in the reference intervals for TSH. The
SHIP-specific reference interval is lower than those for
the general U.S. population and the manufacturer’s [11].
It seems that SHIP patients taking thyroxine are
adjusted to the local reference range, with less subjects
classified as over-treated than when using the manufac-
turer’s reference range (19.5% SHIP-specific vs. 30.5%
manufacturer’s).
Despite regional disparities in the prevalence and pat-
terns of thyroid diseases, we found comparable propor-
tions of subjects with elevated or decreased TSH levels
Figure 1 Proportion of decreased, normal and increased serum thyroid stimulating hormone (TSH) levels according to the local
reference range ( < 50 years: 0.27-2.15 mIU/L; ≥ 50 years: 0.19-2.19 mIU/L) by type of thyroid medication.
Figure 2 Proportion of decreased, normal and increased serum thyroid stimulating hormone (TSH) levels according to the
manufacturer’s reference range ( all ages: 0.3-3.0 mIU/L) by type of thyroid medication.
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27.4% of subjects from our study population had ele-
vated or decreased TSH levels, compared to 33% in the
U.S. NHANES study [2]. Among the SHIP participants
treated with thyroxine, about one-fifth (19.5%) were
over-treated, which is equal to the proportions observed
in the U.K (21% [3] and 23% [4]).
In Germany, huge efforts have been made to raise
awareness and increase and stabilise the iodine intake in
the population. Those efforts have improved the situa-
tion markedly. However, efforts should also be made to
improve thyroid therapy monitoring. As previously
shown, inadequate or excessive thyroxine dosing causes
mild thyroid hypo- and hyperfunction [3].
The standard treatment in patients with hypothyroid-
ism is thyroxine. However, in the absence of screening
programs, patients with thyroid failure may remain
undiagnosed [12,17]. Even mild thyroid hypofunction
may have adverse effects on circulating lipid levels and
may increase the risk of ischemic heart disease [2,18,19].
An elevated TSH level, characteristic of hypothyroidism,
was seen in 10.0% of the SHIP participants taking thyr-
oxine. A decreased TSH level, which represents a risk
factor for developing atrial fibrillation [20] and osteo-
porosis [21], was observed in 19.5% of SHIP participants
taking thyroxine. By exact dose monitoring, adverse
effects resulting from under- or over-treatment can be
minimised. Furthermore, there may be a positive impact
on the cost of thyroid medications, which accounted for
296.5 million € in Germany in 2007 [22].
Potential limitations of our study arise from the use of
medications for non-thyroid diseases in our study popu-
lation. Circulating concentrations of thyroid hormones
are altered by several drugs, such as lithium, amiodar-
one, testosterone, and oestrogen [12,15,23]. Lithium and
amiodarone are both associated with increases in TSH
levels [12]. However, these two substances were rarely
used by SHIP participants. Among the 266 study sub-
jects taking thyroid medication, lithium was used by
two, and amiodarone was not used by any subject.
Therefore, the impact of thesed r u g so nt h ep o p u l a t i o n
level is assumed to be much smaller than that of the
effects of under- and over-treatment. The same reason-
i n ga p p l i e st ot h eu s eo ft e s t o s t e r o n e ,b e c a u s eo n l y1o f
47 men taking thyroid medication was also using testos-
terone. Oestrogen, in contrast, was widely used, with 51
of 219 women reporting concomitant use of thyroid
medication and oestrogen. Since the oestrogen-TSH
association has been shown to be weak [12], we do not
suspect a relevant influence of this medication on our
results. The timing of blood sampling is also unlikely to
be a relevant influence on our results, as the pulsatile
and circadian secretion of TSH is of minor importance
in thyroid disease diagnostics [24]. Furthermore, we do
not consider the missing data on indication for thyroid
medication use or prescribed dose as a limitation, as the
adverse effects of under- or over-treatment with thyroid
medication are independent of these treatment
characteristics.
Major limitations include the small study population
and the low proportion of male subjects, which are due
to the population-based study design. Moreover, infor-
mation on the duration of thyroid medication intake
was not collected. We know that among participants
who reported a history of thyroid surgery, less than 5%
underwent an operation in the year prior to the SHIP
examination. Among the remaining subjects, though, we
cannot rule out that a significant number started thyroid
therapy shortly before participating in SHIP. If this were
the case, those subjects were probably still undergoing
dose adjustment at the time of the SHIP examination
and may not have reached a stable TSH level, which
may have introduced some bias in our study.
Conclusions
We suggest that general practitioners and other care
providers for patients taking thyroid medication should
more carefully monitor the effects of therapy, adjust
dosages and encourage compliance. Further research,
including a health economics evaluation, is needed to
optimise thyroid disease monitoring.
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